Co-targeting SOS1 enhances the antitumor effects of KRAS
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
05 Aug 2024
05 Aug 2024
Historique:
received:
23
01
2023
accepted:
08
07
2024
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
5
8
2024
Statut:
aheadofprint
Résumé
Combination approaches are needed to strengthen and extend the clinical response to KRAS
Identifiants
pubmed: 39103541
doi: 10.1038/s43018-024-00800-6
pii: 10.1038/s43018-024-00800-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency)
ID : 861507
Organisme : Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency)
ID : 867897
Organisme : Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency)
ID : 874517
Organisme : Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency)
ID : 883626
Organisme : Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency)
ID : 892584
Informations de copyright
© 2024. The Author(s).
Références
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M. & Kraut, N. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 12, 924–937 (2022).
pubmed: 35046095
pmcid: 9394389
doi: 10.1158/2159-8290.CD-21-1331
Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug Discov. 19, 533–552 (2020).
pubmed: 32528145
pmcid: 7809886
doi: 10.1038/s41573-020-0068-6
Sacher, A. et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N. Engl. J. Med. 389, 710–721 (2023).
pubmed: 37611121
doi: 10.1056/NEJMoa2303810
Hong, D. S. et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207–1217 (2020).
pubmed: 32955176
pmcid: 7571518
doi: 10.1056/NEJMoa1917239
de Langen, A. J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet 401, 733–746 (2023).
pubmed: 36764316
doi: 10.1016/S0140-6736(23)00221-0
Mok, T. S. K. et al. KRYSTAL-12: a randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation. J. Clin. Oncol. 39, TPS9129 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.TPS9129
Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381 (2021).
pubmed: 34096690
pmcid: 9116274
doi: 10.1056/NEJMoa2103695
Hallin, J. et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020).
pubmed: 31658955
doi: 10.1158/2159-8290.CD-19-1167
Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med. 384, 2382–2393 (2021).
pubmed: 34161704
pmcid: 8864540
doi: 10.1056/NEJMoa2105281
Koga, T. et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J. Thorac. Oncol. 16, 1321–1332 (2021).
pubmed: 33971321
doi: 10.1016/j.jtho.2021.04.015
Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679–683 (2021).
pubmed: 34759319
pmcid: 8887821
doi: 10.1038/s41586-021-04065-2
Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351, 604–608 (2016).
pubmed: 26841430
pmcid: 4955282
doi: 10.1126/science.aad6204
Liu, C. et al. Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling. Clin. Cancer Res. 27, 342–354 (2021).
pubmed: 33046519
doi: 10.1158/1078-0432.CCR-20-2718
Adachi, Y. et al. Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nat. Cancer 4, 829–843 (2023).
pubmed: 37277529
doi: 10.1038/s43018-023-00575-2
Ryan, M. B. et al. KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy. Cell Rep. 39, 110993 (2022).
pubmed: 35732135
pmcid: 9809542
doi: 10.1016/j.celrep.2022.110993
Ryan, M. B. et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition. Clin. Cancer Res. 26, 1633–1643 (2020).
pubmed: 31776128
doi: 10.1158/1078-0432.CCR-19-3523
Amodio, V. et al. EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer. Cancer Discov. 10, 1129–1139 (2020).
pubmed: 32430388
pmcid: 7416460
doi: 10.1158/2159-8290.CD-20-0187
Fakih, M. et al. 434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC). Ann. Oncol. 32, S551 (2021).
doi: 10.1016/j.annonc.2021.08.955
Fedele, C. et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J. Exp. Med. 218, e20201414 (2021).
pubmed: 33045063
doi: 10.1084/jem.20201414
Weiss, J. et al. LBA6 KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann. Oncol. 32, S1294 (2021).
doi: 10.1016/j.annonc.2021.08.2093
Yaeger, R. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 388, 44–54 (2023).
pubmed: 36546659
doi: 10.1056/NEJMoa2212419
Yaeger, R. et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-24-0217 (2024).
Hofmann, M. H. et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 11, 142–157 (2021).
pubmed: 32816843
doi: 10.1158/2159-8290.CD-20-0142
Hillig, R. C. et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc. Natl Acad. Sci. USA 116, 2551–2560 (2019).
pubmed: 30683722
pmcid: 6377443
doi: 10.1073/pnas.1812963116
Hofmann, M. H. et al. Abstract CT210: trial in process: phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan. Cancer Res. 81, CT210–CT210 (2021).
doi: 10.1158/1538-7445.AM2021-CT210
Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111–1116 (2001).
pubmed: 11323676
doi: 10.1038/35074129
Riely, G. J. et al. 99O_PR KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. J. Thorac. Oncol. 16, S751–S752 (2021).
doi: 10.1016/S1556-0864(21)01941-9
Darash-Yahana, M. et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS ONE 4, e6695 (2009).
pubmed: 19690611
pmcid: 2723911
doi: 10.1371/journal.pone.0006695
Cao, Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol. Med. 19, 460–473 (2013).
pubmed: 23773831
doi: 10.1016/j.molmed.2013.05.002
Tang, K. H. et al. Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC. Cancer Discov. 12, 47–61 (2022).
pubmed: 34353854
doi: 10.1158/2159-8290.CD-21-0369
Wagle, M. C. et al. A transcriptional MAPK pathway activity score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis. Oncol. 2, 7 (2018).
pubmed: 29872725
pmcid: 5871852
doi: 10.1038/s41698-018-0051-4
Korbecki, J. et al. The role of CXCL16 in the pathogenesis of cancer and other diseases. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22073490 (2021).
Wu, E. et al. Comprehensive dissection of PDGF–PDGFR signaling pathways in PDGFR genetically defined cells. PLoS ONE 3, e3794 (2008).
pubmed: 19030102
pmcid: 2582946
doi: 10.1371/journal.pone.0003794
Tanaka, N. et al. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 11, 1913–1922 (2021).
pubmed: 33824136
pmcid: 8338755
doi: 10.1158/2159-8290.CD-21-0365
Adachi, Y. et al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin. Cancer Res. 26, 5962–5973 (2020).
pubmed: 32900796
doi: 10.1158/1078-0432.CCR-20-2077
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517
pmcid: 1239896
doi: 10.1073/pnas.0506580102
Young, L. C. & Rodriguez-Viciana, P. MRAS: a close but understudied member of the RAS family. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a033621 (2018).
Quilliam, L. A. et al. M-Ras/R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6. J. Biol. Chem. 274, 23850–23857 (1999).
pubmed: 10446149
doi: 10.1074/jbc.274.34.23850
Depeille, P. et al. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat. Cell Biol. 17, 804–815 (2015).
pubmed: 26005835
pmcid: 4652934
doi: 10.1038/ncb3175
Rodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M. & McCormick, F. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol. Cell 22, 217–230 (2006).
pubmed: 16630891
doi: 10.1016/j.molcel.2006.03.027
Sabari, J. K. et al. KRYSTAL-2: a phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation. J. Clin. Oncol. 39, TPS146 (2021).
doi: 10.1200/JCO.2021.39.3_suppl.TPS146
Johnson, M. L. et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation. Eur. J. Cancer 10.1016/S0959-8049(20)31077-7 (2020).
Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316–329 (2016).
pubmed: 26739882
doi: 10.1158/2159-8290.CD-15-1105
Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature https://doi.org/10.1038/s41586-023-06123-3 (2023).
doi: 10.1038/s41586-023-06123-3
pubmed: 38093009
pmcid: 11216305
Solanki, H. S. et al. Cell type-specific adaptive signaling responses to KRAS(G12C) inhibition. Clin. Cancer Res. 27, 2533–2548 (2021).
pubmed: 33619172
pmcid: 9940280
doi: 10.1158/1078-0432.CCR-20-3872
Misale, S. et al. Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers. Res. Sq. https://doi.org/10.21203/rs.3.rs-1236956/v1 (2022).
Misale, S. et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin. Cancer Res. 25, 796–807 (2019).
pubmed: 30327306
doi: 10.1158/1078-0432.CCR-18-0368
Kimmelman, A. C., Osada, M. & Chan, A. M. R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells. Oncogene 19, 2014–2022 (2000).
pubmed: 10803462
doi: 10.1038/sj.onc.1203530
Marte, B. M., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. & Downward, J. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr. Biol. 7, 63–70 (1997).
pubmed: 8999998
doi: 10.1016/S0960-9822(06)00028-5
Rodriguez-Viciana, P., Sabatier, C. & McCormick, F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell Biol. 24, 4943–4954 (2004).
pubmed: 15143186
pmcid: 416418
doi: 10.1128/MCB.24.11.4943-4954.2004
Ehrhardt, G. R., Leslie, K. B., Lee, F., Wieler, J. S. & Schrader, J. W. M-Ras, a widely expressed 29-kD homologue of p21 Ras: expression of a constitutively active mutant results in factor-independent growth of an interleukin-3-dependent cell line. Blood 94, 2433–2444 (1999).
pubmed: 10498616
doi: 10.1182/blood.V94.7.2433.419k31_2433_2444
Rebhun, J. F., Castro, A. F. & Quilliam, L. A. Identification of guanine nucleotide exchange factors (GEFs) for the Rap1 GTPase. Regulation of MR-GEF by M-Ras-GTP interaction. J. Biol. Chem. 275, 34901–34908 (2000).
pubmed: 10934204
doi: 10.1074/jbc.M005327200
Gao, X. et al. Identification and characterization of RA-GEF-2, a Rap guanine nucleotide exchange factor that serves as a downstream target of M-Ras. J. Biol. Chem. 276, 42219–42225 (2001).
pubmed: 11524421
doi: 10.1074/jbc.M105760200
Castro, A. F. et al. M-Ras induces Ral and JNK activation to regulate MEK/ERK-independent gene expression in MCF-7 breast cancer cells. J. Cell. Biochem. 113, 1253–1264 (2012).
pubmed: 22121046
pmcid: 3303964
doi: 10.1002/jcb.23458
Tabernero, J. et al. P-71 KRYSTAL-10: a randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation. Ann. Oncol. 32, S121 (2021).
doi: 10.1016/j.annonc.2021.05.126
Chen, W. S. et al. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment. Cell Rep. 37, 109974 (2021).
pubmed: 34758313
pmcid: 8656042
doi: 10.1016/j.celrep.2021.109974
Liu, J. J. et al. Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity. Hepatology https://doi.org/10.1002/hep.32555 (2022).
doi: 10.1002/hep.32555
pubmed: 35993161
Ricciuti, B. et al. Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J. Thorac. Oncol. 17, 399–410 (2022).
pubmed: 34740862
doi: 10.1016/j.jtho.2021.10.013
Negrao, M. V. et al. Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 13, 1556–1571 (2023).
pubmed: 37068173
pmcid: 11024958
doi: 10.1158/2159-8290.CD-22-1420
Anastasiou, P. et al. Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity. Cancer Res. 82, 4029–4029 (2022).
BLISS, C. I. The toxicity of poisons applied jointly1. Ann. Appl. Biol. 26, 585–615 (1939).
doi: 10.1111/j.1744-7348.1939.tb06990.x
Waizenegger, I. C. et al. A novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation. Mol. Cancer Ther. 15, 354–365 (2016).
pubmed: 26916115
doi: 10.1158/1535-7163.MCT-15-0617
Sanderson, M. P. et al. The IGF1R/INSR inhibitor BI 885578 selectively inhibits growth of IGF2-overexpressing colorectal cancer tumors and potentiates the efficacy of anti-VEGF therapy. Mol. Cancer Ther. 16, 2223–2233 (2017).
pubmed: 28729397
doi: 10.1158/1535-7163.MCT-17-0336
Ahdesmäki, M., Gray, S., Johnson, J. & Lai, Z. Disambiguate: an open-source application for disambiguating two species in next generation sequencing data from grafted samples. F1000Research https://doi.org/10.12688/f1000research.10082.2 (2017).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886
doi: 10.1093/bioinformatics/bts635
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677
doi: 10.1093/bioinformatics/btt656
Sayols, S., Scherzinger, D. & Klein, H. dupRadar: a Bioconductor package for the assessment of PCR artifacts in RNA-Seq data. BMC Bioinform. 17, 428 (2016).
doi: 10.1186/s12859-016-1276-2
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https://doi.org/10.1101/060012 (2021).
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021
pmcid: 4707969
doi: 10.1016/j.cels.2015.12.004
Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016).
pubmed: 27207943
doi: 10.1093/bioinformatics/btw313
Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 33, 2938–2940 (2017).
pubmed: 28645171
pmcid: 5870712
doi: 10.1093/bioinformatics/btx364
Wilkinson, L. ggplot2: elegant graphics for data analysis by Wickham, H. Biometrics https://doi.org/10.1111/j.1541-0420.2011.01616.x (2011).
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).
doi: 10.1186/1471-2105-14-7
Briere, D. M. et al. The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy. Mol. Cancer Ther. 20, 975–985 (2021).
pubmed: 33722854
pmcid: 8444277
doi: 10.1158/1535-7163.MCT-20-0462